The Food and Drug Administration (FDA) approved Zepbound in December 2024 for treating obstructive sleep apnea (OSA). Medicare Part D may cover Zepbound, but only when a doctor prescribes it for OSA.
The eye does not have a way to remove floaters, so you will have them as long as you live unless you do something about it.
Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
The GLP-1 drug tirzepatide (Zepbound) was recently approved for obstructive sleep apnea in people who are obese, in combination with a healthy diet and physical activity. GLP-1 agonists are quite ...
A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
ResMed’s strong demand for AirSense 11 boosts its earnings outlook. Learn why RMD stock is undervalued with growth ...